Fennec Pharmaceuticals Stock Alpha and Beta Analysis
| FENC Stock | USD 7.90 0.19 2.35% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Fennec Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Fennec Pharmaceuticals over a specified time horizon. Remember, high Fennec Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Fennec Pharmaceuticals' market risk premium analysis include:
Beta 0.78 | Alpha (0.08) | Risk 3.15 | Sharpe Ratio (0.06) | Expected Return (0.18) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Fennec Pharmaceuticals Backtesting, Fennec Pharmaceuticals Valuation, Fennec Pharmaceuticals Correlation, Fennec Pharmaceuticals Hype Analysis, Fennec Pharmaceuticals Volatility, Fennec Pharmaceuticals History and analyze Fennec Pharmaceuticals Performance. Fennec Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Fennec Pharmaceuticals market risk premium is the additional return an investor will receive from holding Fennec Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Fennec Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Fennec Pharmaceuticals' performance over market.| α | -0.08 | β | 0.78 |
Fennec Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Fennec Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Fennec Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Fennec Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Fennec Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Fennec Pharmaceuticals shares will generate the highest return on investment. By understating and applying Fennec Pharmaceuticals stock market price indicators, traders can identify Fennec Pharmaceuticals position entry and exit signals to maximize returns.
Fennec Pharmaceuticals Return and Market Media
The median price of Fennec Pharmaceuticals for the period between Tue, Sep 30, 2025 and Mon, Dec 29, 2025 is 8.18 with a coefficient of variation of 7.89. The daily time series for the period is distributed with a sample standard deviation of 0.65, arithmetic mean of 8.29, and mean deviation of 0.55. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 26900 shares by Southpoint Capital Advisors Lp of Fennec Pharmaceuticals at 9.5871 subject to Rule 16b-3 | 10/07/2025 |
2 | Acquisition by Raykov Rosty of 4609 shares of Fennec Pharmaceuticals at 2.45 subject to Rule 16b-3 | 10/08/2025 |
3 | Disposition of 20609 shares by Southpoint Capital Advisors Lp of Fennec Pharmaceuticals at 9.3461 subject to Rule 16b-3 | 10/09/2025 |
4 | Acquisition by Rallis Chris A of 1960 shares of Fennec Pharmaceuticals at 2.55 subject to Rule 16b-3 | 10/10/2025 |
5 | Can Fennec Pharmaceuticals Inc. stock maintain growth trajectory - Weekly Risk Summary Weekly Momentum Picks - newser.com | 11/04/2025 |
6 | Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada | 11/18/2025 |
7 | Major Shareholder Sells Off Fennec Pharmaceuticals Stock - TipRanks | 11/20/2025 |
8 | Adherex Technologies Stock Rating Lowered by Wall Street Zen | 11/25/2025 |
9 | Acquisition by Raykov Rosty of 5208 shares of Fennec Pharmaceuticals subject to Rule 16b-3 | 12/01/2025 |
10 | Pedmark Delivers In Japan Study Less Hearing Loss, Same Cancer-Fighting Power | 12/02/2025 |
11 | Brokerages Set Adherex Technologies Inc. Price Target at 13.33 | 12/04/2025 |
12 | Analysts Offer Insights on Healthcare Companies Fennec Pharmaceuticals and Pfizer - The Globe and Mail | 12/10/2025 |
13 | Portfolio Update How Fennec Pharmaceuticals Inc. stock trades before earnings - Watch List Risk Managed Trade Strategies - ulpravda.ru | 12/19/2025 |
14 | Southpoint holdings in Fennec Pharmaceuticals Inc. | 12/26/2025 |
About Fennec Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Fennec or other stocks. Alpha measures the amount that position in Fennec Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 1.29 | 0.86 | 0.9 | Revenue Per Share | 0.8 | 1.74 | 1.83 |
Fennec Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Fennec Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fennec Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Fennec Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Fennec Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Fennec Pharmaceuticals' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Fennec Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Fennec Pharmaceuticals Backtesting, Fennec Pharmaceuticals Valuation, Fennec Pharmaceuticals Correlation, Fennec Pharmaceuticals Hype Analysis, Fennec Pharmaceuticals Volatility, Fennec Pharmaceuticals History and analyze Fennec Pharmaceuticals Performance. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Fennec Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.